China Pharma Holdings Profit Margin

The latest profit margin for CPHI is -94.26% as of June 2026. That compares with -85.11% in the prior-year period — down 10.8% year over year. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside China Pharma Holdings's historical trend and sector peers before judging valuation or financial health.

Over the past year, CPHI's profit margin moved from -85.11% to -94.26% — a 10.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in China Pharma Holdings's valuation or profitability profile.

Against Healthcare companies, CPHI currently prints -94.26% for profit margin, while the sector average sits near 13.89%. That is roughly 778.9% below the sector mean. Large gaps often invite a closer look at China Pharma Holdings's growth, margins, and balance sheet.

Profit Margin shows how effectively China Pharma Holdings converts resources into returns. At -94.26%, CPHI may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -85.11% in the prior-year period — down 10.8% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting CPHI's profit margin (-94.26%), review year-over-year change from -85.11%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.